Table 3.

Result of previously reported SNPs

SNP	Chr.	Chr. location	Gene	Relative Pos.	Case			Control			Ptrenda	ORb	RAFb		Alleleb
					11	12	22	11	12	22			Case	Control	1	2
rs17674580	18	43309911	SLC14A1	0	5	86	439	28	579	4619	1.8 × 10−4	1.54	0.091	0.061	A	G
rs1014971	22	39332623	APOBEC3A	−20904	117	256	157	920	2545	1761	0.0074	1.19	0.462	0.420	T	C
rs2294008	8	143761931	PSCA	0	241	228	61	2079	2416	730	0.0092	1.20	0.670	0.629	T	C
rs9642880	8	128718068	MYC	−30247	63	226	241	491	2165	2569	0.039	1.15	0.332	0.301	T	G
rs798766	4	1734239	TACC3	0	15	174	341	154	1461	3611	0.056	1.17	0.192	0.169	A	G
rs11892031	2	234565283	UGT1A8	0	526	4	0	5143	83	0	0.13	2.11	0.996	0.992	T	G
rs1495741	8	18272881	NAT2	14158	55	232	244	559	2394	2628	0.62	1.03	0.322	0.315	A	G
rs401681	5	1322087	CLPTM1L	0	229	245	56	2359	2288	579	0.64	0.97	0.663	0.670	G	A
rs710521	3	189645933	LEPREL1	28584	298	203	29	2948	1996	282	0.92	0.99	0.754	0.755	T	C
rs8102137	19	30296853	CCNE1	−6048	2	89	439	37	834	4355	0.92	0.99	0.912	0.913	G	A

We analyzed 539 bladder cancer cases and 5581 controls at GWAS stage. Chr., chromosome; Pos., position in the NCBI Build 36.3.

^aP-values were obtained from Cochrane-Armitage trend test.

^bAllele 1 is a risk allele in the previous GWAS studies. OR was calculated using allele 2 as a reference.